The FDA has approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic...
Telix Pharmaceuticals announces that the FDA has approved a supplementary New Drug Application (sNDA) for Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is indicated.
This medicinal product is for diagnostic use only. After radiolabelling with gallium ( 68 Ga) chloride solution, the solution of gallium ( 68 Ga) edotreotide obtained is indicated for Positron Emission Tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours (GEP-NET) for localizing primary tumours and their metastases.
Genentech/Roche have announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the...
Advanced Accelerator Applications has announced that following a positive opinion issued by the European Medicines Agency in October 2016, the...
Data from the Phase III GALLIUM study (Abstract #6), presented at the American Society of Hematology (ASH) annual congress, demonstrate...
The main goal is to compare the prevalence of patients with metastatic RAI-non-avid or RAI-non-responsive thyroid cancer whose tumors are characterized by a high SSTR2 expression by imaging with 68Ga-DOTATATE PET/CT between three groups...
This medicinal product is for diagnostic use only. Locametz, after radiolabelling with gallium-68, is a radioactive diagnostic agent indicated for the identification of prostate-specific membrane antigen (PSMA)-positive lesions by positron emission tomography (PET) in adult patients with prostate cancer.